CELANESE CORPORATION (CE): what the price assumes

In the published model solve dated 2026-Q2, anchored at $44.67, CELANESE CORPORATION (CE) is priced for +7.1% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/CE

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 6% sits below it).

How unusual the bet is: n/a

Valuation X-Ray

The price is supported by earnings-power value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 2.9%); the inversion above states its own rate.

Per-Model Detail (n=6)

Economic-Unit Decomposition (Sum Of The Parts)

Material operating units span distinct economics, so a single sector multiple or target margin is not representative. Consolidated cash-flow lenses may remain as secondary checks, while segment SOTP is primary.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 6.7%); the trailing year was depressed.

Bullet Takeaways

• Across a full cycle Celanese has run operating margins of about 6.7%; over the trailing twelve months that same margin was -6.9%, and the distance between those two numbers is the entire investment case.
• The balance sheet carries 14.5 billion dollars of debt, and even on through-cycle economics the operating profit covers the interest bill only about 0.9 times, with the 10-K warning that cash flow will "be dedicated to the payment of principal and interest on indebtedness" rather than to operations or expansion.
• Second-quarter results land August 4, 2026, and the question they answer is whether the price increases announced across the acetyl chain in May held.

Bull Case

One number decides this company, and it is neither the share price nor the debt. It is the operating margin Celanese earns across a full cycle. Through the cycle that figure is about 6.7%. Over the last twelve months it was -6.9%. On roughly 9.5 billion dollars of revenue, each percentage point of operating margin is worth about 95 million dollars of profit, so the swing between those two numbers is larger than the company's entire market value. Everything else in this report is downstream of whether the first number or the second one is the real one.

The case for the first is that the trough has a visible mechanical cause and a visible mechanical fix. Celanese runs two segments, Engineered Materials at 56% of revenue and the Acetyl Chain at 44%, and the Acetyl Chain is the one that decides the cycle. Its pricing behaves in a specific way that the 10-K spells out: prices are set on "value-in-use and is generally independent of changes in the cost of raw materials. Therefore, in general, margins may expand or contract in response to changes in raw material costs". Read that carefully, because it cuts the way the bull wants. When methanol, ethylene and natural gas get cheaper, the selling price does not automatically follow them down, and the spread widens. The margin is not a function of demand alone.

The second structural feature is optionality inside the chain. The company describes managing the Acetyl Chain "by leveraging its ability to sell chemicals externally to end-use markets or downstream to its acetate tow, intermediate chemistry, emulsion polymers, redispersible powders and ethylene vinyl acetate polymers businesses". A molecule of acetic acid can be sold, or it can be pushed one step further into a product with a better spread that week. Most commodity chemical producers make that decision once, when they build the plant. Celanese makes it continuously.

Meanwhile capacity is leaving the industry, including its own. The 10-K records lower depreciation in 2025 tied to the 2024 closures of polymerization units in Uentrop, Germany and a facility in Mechelen, Belgium, and in June the company announced the closure of an Engineered Materials compounding site in Ulsan, South Korea. Capacity that comes out in a trough does not come back quickly, which is what makes recoveries in this industry sharper than the demand data alone would suggest.

The peer set says the same thing in a different way. Nobody in either cohort is earning well right now. In Engineered Materials, HUNTSMAN (HUN) is running a -3.3% operating margin and ROGERS (ROG) is at -4.1%; AVIENT (AVNT), the exception, manages 9.1%. In the acetyl cohort, LYONDELLBASELL (LYB) is at -1.0% and OLIN (OLN) at -1.7%, with revenue down 9.4% at LYB. When the largest and the smallest producers in a sector are all losing money at the operating line at the same time, the diagnosis is a cycle rather than a company.

The last piece is what happens to the equity if the diagnosis is right. Celanese generated free cash flow of about 878 million dollars over the trailing year despite the reported loss, because the loss is loaded with non-cash charges. The 10-K states the plan for that cash directly: "to continue to allocate, capital to repay and reduce our outstanding debt using cash from operations and proceeds from asset sales or dispositions in cases where we are able to do so on favorable terms". The dividend has been reduced to a token three cents a share. In a company where debt is nearly three times the market value of the equity, every dollar of debt repaid transfers to the shareholder, and it transfers with leverage.

Bear Case

The price is not being paid for what Celanese earns. It is being paid for what Celanese is assumed to earn after the cycle turns, and that assumption is doing more work here than in almost any name of comparable size. At $46.42 the market is paying roughly 27 times a through-cycle operating profit that the company is not currently producing, and then asking that profit to compound at about 7.3% a year for five years on top. The trailing operating result is a loss of 663 million dollars. The bet is not that Celanese is cheap. The bet is that a mid-cycle Celanese exists and arrives soon enough.

The most fragile assumption in that stack is not the growth rate. It is the through-cycle margin itself, because even if that margin returns exactly as modelled, the arithmetic barely works. Total debt is 14.5 billion dollars, which is about 22 times operating profit measured through the cycle. On that same through-cycle basis the interest bill is covered roughly 0.9 times. A normal recovery does not fix this. A normal recovery leaves the company approximately paying its interest and nothing else, which is why the entire capital allocation plan is debt reduction and why the dividend is now three cents.

The 10-K does not dress this up. It warns that cash flow will "be dedicated to the payment of principal and interest on indebtedness and amounts payable in connection with the satisfaction of our other liabilities, therefore reducing our ability to use our cash flow to fund operations, capital expenditures and future business opportunities or pay dividends on or repurchase our common stock". The deleveraging plan itself carries a conditional worth reading twice: the company intends to reduce debt using cash from operations and proceeds from asset sales "in cases where we are able to do so on favorable terms". Every peer in both cohorts is in the same trough at the same time, which is not the market in which favorable terms are typically available.

Two external variables can move the outcome and neither is under management's control. The first is feedstock and energy, which the risk factors name explicitly as "volatility or changes in the price and availability of raw materials and energy, particularly changes in the demand for, supply of, and market prices of ethylene, methanol, natural gas, carbon monoxide, wood pulp". The same mechanic that widens spreads when input costs fall compresses them when input costs rise. The second is credit, and the risk list names "additional downgrades" among the things that could go wrong. A downgrade raises the cost of refinancing a debt stack this size at exactly the moment operating profit is least able to absorb it.

Then there is the question of what actually supports the price. Two approaches reach it, and both lean on an input the cycle has distorted. The earnings-power lens gets there by capitalizing a normalized profit stream at a discount rate below 3%, which is a rate no lender charges this balance sheet. The peer-multiple lens gets there by applying a sector price-to-sales reference to revenue, a method that by construction cannot see an operating loss. The lenses that do not depend on either input sit under the quote: the price stands about 40% above the asset-value family, which for a company with book value of $36.94 a share is simply the observation that the market is already paying a premium to what the balance sheet says the assets are worth.

The downside is not unbounded. Celanese holds about 1.15 billion dollars of equity stakes outside its operating segments, roughly a fifth of the company's market value, and those stakes retain value independently of what happens to acetyl spreads. That is the floor. It is a real one, and it is also a reminder of the shape of the bet: a fifth of what an investor pays today is not the operating business at all.

Valuation

Trailing earnings cannot anchor this one. Celanese lost money at the operating line over the last twelve months, so the multiple that matters is computed on the company's own through-the-cycle margins applied to current revenue rather than on the trough quarter. On that basis the price works out to roughly 27 times operating profit, and inverting it produces an embedded assumption of about 7.3% annual operating-profit growth over five years, layered on top of a recovery that has not happened yet.

Hold the two margin numbers side by side, because they are the whole disagreement. Over the trailing twelve months the operating margin was -6.9%. Measured through the cycle, on the company's own history, it is 6.7%. The valuation assumes the second is the true economics of the business and the first is weather. That may well be right. It is worth being explicit that it is an assumption rather than an observation, and that the price already reflects it.

The reading is also unusually sensitive to the discount rate, more so than for most companies: each additional percentage point of cost of capital moves the required operating profit by roughly 9 percentage points. Treat the 7.3% as an order of magnitude rather than a measurement. The rate used here, 7%, is itself a floor rather than a computed figure, because the risk-adjusted rate the model arrives at for this balance sheet lands below it.

Where the methods land is more informative than any single figure. Only two families reach the price. The earnings-power approach reaches it by capitalizing a normalized operating profit at a discount rate under three percent, and the peer-multiple approach reaches it by applying a sector price-to-sales reference to revenue, which is a lens that cannot see an operating loss at all. The other two sit under the quote: the price stands about 40% above the asset-value family and about 27% above the forward-growth family. That is not the profile of a cheap stock supported by conservative methods. It is a profile where the conservative methods say the price is already ahead of the assets and the forward cash flows, and the two that agree with the price only do so on inputs the cycle has bent.

Book value is the cleanest of those anchors. Shareholders' equity works out to $36.94 a share, and the shares change hands above that level. For a business whose plants are its assets and whose plants are currently underused, paying more than book is a statement about the recovery, not about the steel.

The cohort confirms the trough without excusing it. In the Engineered Materials group, AVNT earns a 9.1% operating margin on 3.3 billion dollars of revenue and HUN is at -3.3%; in the acetyl group, LYB is at -1.0% on 29.7 billion dollars and OLN at -1.7%. Celanese sits inside that distribution rather than outside it. What separates it is the financing. Debt of 14.5 billion dollars against a 5.1 billion dollar equity value means the enterprise is roughly three quarters lender-owned, so the same cyclical swing that moves a peer's shares moves these several times harder in both directions.

The balance sheet closes the section because it sets the clock. Free cash flow ran about 878 million dollars over the trailing year, which is the reason a company reporting an operating loss is not in immediate distress, and the share count has been roughly flat, rising about 0.2% a year over the four years to March 2026. What the balance sheet does not offer is patience. Interest is covered about 0.9 times on through-cycle profit, so the recovery this price assumes is not merely desirable. It is the mechanism by which the debt gets serviced from operations rather than from asset sales.

Catalysts

The next scheduled event is second-quarter reporting on August 4, 2026, with the call the following morning. The line to watch is not revenue. It is segment operating profit in the Acetyl Chain, because that is where a spread recovery would show up first and where the reported loss originated.

Management has been testing pricing directly. Price increases were announced across acetyl chain products on May 11, 2026 and across engineered materials products on May 19, 2026. Announced increases and realized increases are different things in a commodity chemical market with idle capacity, and the August print is the first place the difference becomes visible. On the cost side, the company announced the closure of its Engineered Materials compounding facility in Ulsan, South Korea on June 4, 2026, continuing a pattern of taking capacity out rather than waiting for demand to fill it.

Two smaller items round out the picture. The quarterly dividend was declared at three cents a share on July 15, 2026, with an ex-dividend date of July 28, 2026, which confirms that free cash flow is being routed to the balance sheet rather than to holders. And JPMorgan upgraded the shares to Overweight in May 2026 with a $68 target. That target credits a mid-cycle recovery arriving on a specific timetable; nothing in the company's filed results yet dates it.

Peer Cohorts (Per Segment, With Filing Citations)

Engineered Materials (reported)

• AVNT (AVIENT CORPORATION)
• FY2025 10-K: …and/or biomaterial technologies. We also have what we believe is the broadest composite platform of solutions, which include a full range of thermoset and thermoplastic composites, reinforced with glass, carbon, aramid, and ultrahigh molecular weight polyethylene fibers. These solutions meet a wide variety of unique…
• FY2025 10-K: …reduced energy use, light weighting, and renewable energy applications. Our colorant and additives concentrates are used in a broad range of polymers, including those used in medical and pharmaceutical devices, food packaging, personal care and cosmetics, transportation, building products, wire and cable markets. We…
• EMN (EASTMAN CHEMICAL CO)
• FY2025 10-K: …(Fo Gang) Specialty Resins Limited Chang Chun Petrochemical Co., Ltd. polyvinyl alcohol butyraldehyde 2-ethyl hexanol ethanol triethylene glycol vinyl acetate monomer transportation (automotive safety glass, automotive acoustic glass, and HUD) building and construction (PVB for architectural interlayers) Performance…
• FY2025 10-K: …and compostable cellulosic biopolymer, replaces single-use, traditional materials in food packaging and quick-service restaurants such as straws, cutlery, and protein trays. 8 Tab le of Contents Eastman is positioned to enhance the quality of life in a material way with its sustainable solutions. The Company's…
• HUN (Huntsman Corporation)
• FY2025 10-K: …of suppliers. We consume certain amines produced by our Performance Products segment and isocyanates produced by our Polyurethanes segment, which we use to formulate our Advanced Materials products. For additional information about our risks of raw material supply chain disruptions, see "Part I. Item 1A. Risk…
• FY2025 10-K: …is purchased pursuant to long-term contracts and delivered to our Pensacola, Florida site by barge and to our facility in Geismar, Louisiana via pipeline. For additional information about our risks of raw material supply chain disruptions, see "Part I. Item 1A. Risk Factors." Competition There are a small number of…
• CC (Chemours Co)
• FY2025 10-K: …by product line and markets served. Our Advanced Performance Materials segment maintains a fleet of railcars, tank trucks, containers, and totes to deliver our products and support our supply chain needs. For the portion of the fleet that is leased, the related lease terms are usually staggered, which provides us…
• FY2025 10-K: …the cyclicality of key end markets, such as industrial, chemical processing, consumer goods, and transportation, and is expected to grow in line with GDP. However, with growing demand for cleaner and faster technologies, demand for products in the performance solutions portfolio is expected to grow at a rate faster…
• ROG (Rogers Corporation)
• FY2025 10-K: …the loss of any one of our larger customers would require a period of adjustment, during which the results of operations could be materially adversely impacted, we believe that such events could be successfully mitigated over a period of time due to the diversity of our customer base. We employ a technical sales and…
• FY2025 10-K: …consolidation in Belgium, partially offset by lower volume and related utilization headwinds and unfavorable yield performance. Elastomeric Material Solutions (Dollars in millions) 2025 2024 Net sales $ 349.7 $ 360.9 Gross margin $ 119.7 $ 138.5 Percentage of net sales 34.2 % 38.4 % Our EMS operating segment net…

Acetyl Chain (reported)

• LYB (LYONDELLBASELL INDUSTRIES N.V.)
• FY2025 10-K: …and to a lesser extent from third parties. Raw materials for the non-U.S. production of PO and its co-products are obtained from our O&P-EAI segment and from third parties. We consume a significant portion of our internally produced PO in the production of PO derivatives. The raw material requirements not sourced…
• FY2025 10-K: 131 Table of Contents Exhibit Number Description 10.28 Acknowledgement of Amendment to Receivables Purchase Agreement, dated October 8, 2020, among Lyondell Chemical Company, as servicer, LYB Receivables LLC, as seller, the conduit purchasers, related committed purchasers, LC participants and purchaser agents party…
• DOW (Dow Inc.)
• FY2025 10-K: …UCARSOL ™ Amines and related technology for carbon capture and gas treating, ethanolamines, ethylene oxide ("EO"), ethyleneamines, ELEVATE ™ Additives for enhanced oil recovery, UCON ™ Fluids, DOWANOL ™ Glycol Ethers, DOWTHERM ™ Heat Transfer Fluids, DOWFROST ™ Fluids for data center cooling; higher glycols,…
• FY2025 10-K: Notes due March 15, 2032 DOW/32 New York Stock Exchange The Dow Chemical Company 1.875% Notes due March 15, 2040 DOW/40 New York Stock Exchange The Dow Chemical Company 4.625% Notes due October 1, 2044 DOW/44 New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None Indicate by check…
• OLN (Olin Corporation)
• FY2025 10-K: …the Chlor Alkali Products and Vinyls segment to generate caustic soda production and sales. Chlorine and caustic soda used in our Epoxy segment are transferred at cost from the Chlor Alkali Products and Vinyls segment. The following table lists the principal products and services of our Epoxy segment: Products &…
• FY2025 10-K: …water treatment chemicals and a variety of other organic and inorganic chemicals. A significant portion of chlorine production is consumed in the manufacturing of vinyls intermediates, EDC and VCM, both of which our Chlor Alkali Products and Vinyls segment produces. A large portion of our EDC production is utilized…
• EMN (EASTMAN CHEMICAL CO)
• FY2025 10-K: …and operational excellence. Examples include produced acetic anhydride used in the manufacturing of cellulosic biopolymers and acetyl stream product lines, propylene and ethylene used in the production of olefin derivative product lines such as oxo alcohols and plasticizers. The CI segment also provides superior…
• FY2025 10-K: …at the Kingsport, Tennessee site, which is supplied from Eastman's vertically integrated gasification facility and is the largest and most integrated acetate tow site in the world. The Fibers segment also expects to benefit from Eastman's carbon renewal technology, which enables the substitution of fossil feedstock…
• HUN (Huntsman Corporation)
• FY2025 10-K: …is approximately 0.4 billion pounds. Our amines facilities are located globally. These facilities have a competitive cost base and use modern manufacturing units that allow for flexibility in production capabilities and technical innovation. Several of our facilities are located within large integrated petrochemical…
• FY2025 10-K: …of suppliers. We consume certain amines produced by our Performance Products segment and isocyanates produced by our Polyurethanes segment, which we use to formulate our Advanced Materials products. For additional information about our risks of raw material supply chain disruptions, see "Part I. Item 1A. Risk…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.